| human | Q5 |
| P10058 | IRIS UNIBO author ID | 104804 |
| P496 | ORCID iD | 0000-0001-9286-1913 |
| 0000-0002-9204-1728 | ||
| P1053 | ResearcherID | J-8292-2018 |
| P1153 | Scopus author ID | 26424613300 |
| P734 | family name | Gelsomino | Q37263874 |
| Gelsomino | Q37263874 | ||
| Gelsomino | Q37263874 | ||
| P735 | given name | Francesco | Q2268455 |
| Francesco | Q2268455 | ||
| F. | Q19803502 | ||
| F. | Q19803502 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q39384997 | A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event |
| Q57762661 | Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer |
| Q37952236 | Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. |
| Q93357527 | Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding |
| Q57725981 | Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients |
| Q98177936 | Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) |
| Q56380345 | Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab |
| Q39013047 | Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements. |
| Q54582444 | Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. |
| Q58586458 | Complete recalcification following arterial embolization of massive osteolytic bone metastasis from non-small cell lung cancer (NSCLC) |
| Q44407561 | Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). |
| Q87227033 | Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations? |
| Q38435145 | Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer? |
| Q53281945 | EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. |
| Q58086856 | Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations |
| Q33892582 | Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). |
| Q100414965 | Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer |
| Q38470406 | FGFR as potential target in the treatment of squamous non small cell lung cancer |
| Q57763406 | Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer |
| Q39009124 | First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. |
| Q56352164 | Immune-mediated cholangitis: is it always nivolumab's fault? |
| Q38293725 | Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations |
| Q38153827 | MET and ALK as targets for the treatment of NSCLC. |
| Q38260120 | MET and Small-Cell Lung Cancer |
| Q38996107 | Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review. |
| Q98386283 | New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event |
| Q56960955 | Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury |
| Q38640845 | Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence |
| Q94452299 | Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) |
| Q52983636 | Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC. |
| Q38863105 | Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer |
| Q50140953 | Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques? |
| Q90352700 | Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer |
| Q37952233 | Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. |
| Q38172700 | Targeting the MET gene for the treatment of non-small-cell lung cancer |
| Q91043026 | The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC |
| Q38841082 | The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer |
| Q90345439 | Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer |
Search more.